Trevi Therapeutics, Inc.

TRVI

Trevi Therapeutics, Inc.

TRVI

Insider Sentiment (TTM):

Last Purchase:2022-04-11Last Sale:2025-03-25Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:134,700,195Shares Outstanding:145,592,901Institutional Ownership Pct.:92.52%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	54	19	19	57	117	19	34	16	13	14	32	26
Assets Current
Assets Current	326	176	192	198	207	106	109	67	72	77	88	94
Marketable Securities Current	265	152	169	138	87	84	74	49	57	59	51	63
Prepaid Expense Current	4	2	1	1	2	2	1	1	2	3	4	4
Other Assets Current	3	2	2	2	2	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	1	1	1	1	1	1	1	1	1	1	1	1
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	4	3	1	0	0	0	0	0	0	0	0	0
Finance Lease Right Of Use Asset	-	-	0	0	0	-	0	0	0	0	0	0
Assets	331	180	193	199	208	107	111	69	74	79	89	96
Liabilities And Stockhold…
Accounts Payable Current	3	2	4	3	3	1	3	2	2	2	2	1
Accrued Liabilities Current	5	5	6	6	6	5	7	7	5	3	4	4
Liabilities Current
Liabilities Current	9	7	10	9	9	7	11	9	7	5	6	5
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Finance Lease Liability Current	-	-	0	0	0	-	0	0	0	0	0	0
Operating Lease Liability Noncurrent	0	0	0	1	1	1	1	1	1	1	1	1
Finance Lease Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities	9	7	10	10	10	8	11	10	8	6	7	6
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	683	515	513	511	508	397	387	334	329	322	322	321
Stockholders Equity
Stockholders Equity	322	172	183	190	198	99	100	59	66	72	83	90
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-361	-343	-330	-321	-310	-297	-287	-276	-262	-250	-239	-231
Liabilities And Stockholders Equity	331	180	193	199	208	107	111	69	74	79	89	96
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0	0.001	0.001	0.001	0	0.001	0.001	0.001	0	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0	0.001	0.001	0.001	0	0.001	0.001	0.001	0	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	142	128	128	128	122	100	94	75	73	69	68	64
Shares Outstanding	142	128	128	128	122	100	94	75	73	69	68	64

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-3.55%	23.81%	19.61%	-	-	-	-	-	-	-	-	-
2025	-1.36%	-14.85%	19.24%	-0.62%	20.14%	43.97%	17.54%	3.75%	-8.64%	17.87%	29.58%	19.12%
2024	-11.38%	2.76%	12.07%	12.86%	18.93%	11.43%	-7.10%	37.74%	26.13%	-15.24%	0.61%	7.62%
2023	-	-	-	-3.77%	-8.79%	-27.62%	-18.08%	-1.11%	15.13%	-17.51%	-22.88%	-31.07%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	37.28	24.75	19.66	21.93	22.42	15.38	10.41	7.38	10.68	14.55	15.03	18.16
Quick Ratio	36.80	24.44	19.53	21.78	22.23	15.16	10.32	7.25	10.42	13.94	14.41	17.38
Working Capital	316.97M	169.01M	181.91M	189.26M	197.99M	98.76M	98.92M	58.21M	65.38M	71.49M	81.72M	88.78M
Leverage & Debt
Debt to Equity	0.03	0.04	0.06	0.05	0.05	0.08	0.11	0.17	0.12	0.09	0.08	0.07
Interest Coverage TTM	-	-	-	-51,350.00	-25,760.50	-17,029.33	-12,881.00	-6,887.86	-4,797.00	-237.68	-86.76	-47.88
Debt Ratio	0.03	0.04	0.05	0.05	0.05	0.07	0.10	0.14	0.10	0.08	0.08	0.07
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.33	-0.31	-0.32	-0.32	-0.36	-0.40	-0.47	-0.44	-0.38	-0.34	-0.29	-0.27
Free Cash Flow Per Share TTM	-0.32	-0.31	-0.31	-0.21	-0.22	-0.35	-0.38	-0.35	-0.33	-0.34	-0.32	-0.32
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	8.05%	-3.67%	-10.75%	3.48%	21.99%	41.06%	64.84%	65.68%	41.94%	18.93%	-0.30%	-16.84%
EPS Growth (1Y)	-10.06%	-22.18%	-32.46%	-27.77%	-5.44%	19.36%	60.09%	62.48%	38.65%	17.84%	-35.02%	-42.32%
Valuation Metrics
P/E TTM	-57.15	-38.08	-39.45	-28.95	-15.07	-15.62	-8.77	-7.63	-7.77	-10.23	-4.57	-8.09
P/B TTM	9.08	10.09	9.21	7.00	3.59	7.44	4.22	5.74	4.55	4.75	1.61	2.42
Market Cap	2.92B	1.74B	1.69B	1.33B	713.02M	739.77M	420.12M	338.28M	301.10M	343.33M	132.70M	216.53M
Enterprise Value	2.87B	1.72B	1.67B	1.27B	595.96M	720.40M	386.06M	322.29M	288.23M	329.65M	100.46M	190.75M
Calculated Values
Free Cash Flow TTM	-49.55M	-45.42M	-42.10M	-30.55M	-29.21M	-41.30M	-38.29M	-35.12M	-32.86M	-34.12M	-31.90M	-31.97M
Net Debt	-54.30M	-19.41M	-18.91M	-56.87M	-117.06M	-19.37M	-34.07M	-15.99M	-12.87M	-13.69M	-32.24M	-25.78M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-03-25Sale

Owner: Sciascia, Thomas

Title: Chief Scientific Officer

Shares: 2,631

Price/Share: $6.60

Value: $17,364.60

Shares Owned: 221,373

Relationship: Officer

Ownership: Direct

2025-03-21Sale

Owner: Good, Jennifer L

Title: President & CEO

Shares: 5,263

Price/Share: $6.58

Value: $34,630.54

Shares Owned: 213,313

Relationship: Director,Officer

Ownership: Direct

2025-03-10Sale

Owner: Simon, Farrell

Title: Chief Commercial Officer

Shares: 81,313

Price/Share: $6.94

Value: $564,312.22

Shares Owned: 76,900

Relationship: Officer

Ownership: Direct

2024-09-09Sale

Owner: Good, Jennifer L

Title: President & CEO

Shares: 1,840

Price/Share: $3.04

Value: $5,593.60

Shares Owned: 213,313

Relationship: Director,Officer

Ownership: Direct

2024-09-05Sale

Owner: Good, Jennifer L

Title: President & CEO

Shares: 40,277

Price/Share: $3.11

Value: $125,261.47

Shares Owned: 213,313

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-03-25	Sciascia, Thomas	Officer	Chief Scientific Officer	Direct	Sale	2,631	6.60	$17,364.60	221,373	4
2025-03-21	Good, Jennifer L	Director,Officer	President & CEO	Direct	Sale	5,263	6.58	$34,630.54	213,313	4
2025-03-10	Simon, Farrell	Officer	Chief Commercial Officer	Direct	Sale	81,313	6.94	$564,312.22	76,900	4
2024-09-09	Good, Jennifer L	Director,Officer	President & CEO	Direct	Sale	1,840	3.04	$5,593.60	213,313	4
2024-09-05	Good, Jennifer L	Director,Officer	President & CEO	Direct	Sale	40,277	3.11	$125,261.47	213,313	4
2024-08-27	Meeker, David P	Director	-	Direct	Sale	4,555	2.93	$13,346.15	352,489	4
2024-08-19	Sciascia, Thomas	Officer	Chief Scientific Officer	Direct	Sale	16,496	2.96	$48,828.16	220,315	4
2024-08-16	Sciascia, Thomas	Officer	Chief Scientific Officer	Direct	Sale	18,660	2.76	$51,501.60	220,315	4
2024-05-29	Sciascia, Thomas	Officer	Chief Scientific Officer	Direct	Sale	53,368	2.55	$136,088.40	214,433	4
2024-05-22	Delfini, Lisa	Officer	Chief Financial Officer	Direct	Sale	4,350	2.64	$11,484.00	53,279	4
2024-05-20	Good, Jennifer L	Director,Officer	President & CEO	Direct	Sale	25,037	2.86	$71,605.82	213,313	4
2024-05-10	Good, Jennifer L	Director,Officer	President & CEO	Direct	Sale	4,578	2.90	$13,276.20	213,313	4
2023-10-11	Delfini, Lisa	Officer	Chief Financial Officer	Direct	Sale	785	2.02	$1,585.70	35,901	4
2023-09-11	Delfini, Lisa	Officer	Chief Financial Officer	Direct	Sale	711	2.20	$1,564.20	34,394	4
2023-08-11	Delfini, Lisa	Officer	Chief Financial Officer	Direct	Sale	682	2.36	$1,609.52	32,814	4
2023-07-11	Delfini, Lisa	Officer	Chief Financial Officer	Direct	Sale	687	2.34	$1,607.58	31,204	4
2023-06-12	Delfini, Lisa	Officer	Chief Financial Officer	Direct	Sale	610	2.64	$1,610.40	29,599	4
2023-05-11	Delfini, Lisa	Officer	Chief Financial Officer	Direct	Sale	562	2.89	$1,624.18	27,918	4
2023-04-11	Delfini, Lisa	Officer	Chief Financial Officer	Direct	Sale	840	1.84	$1,545.60	26,189	4
2023-03-13	Delfini, Lisa	Officer	Chief Financial Officer	Direct	Sale	892	1.75	$1,561.00	24,737	4
2023-02-13	Delfini, Lisa	Officer	Chief Financial Officer	Direct	Sale	8,474	2.45	$20,761.30	23,338	4
2022-07-05	Winkelried, Jon, Tpg Gp A…	Other	-	Indirect	Sale	63,569	3.11	$197,699.59	3,824,883	4
2022-06-30	Winkelried, Jon, Tpg Gp A…	TenPercentOwner	-	Indirect	Sale	429,838	2.77	$1,190,651.26	4,324,883	4
2022-05-02	Coulter, James G, Bonderm…	TenPercentOwner	-	Indirect	Sale	600	2.70	$1,620.00	4,800,849	4
2022-04-29	Coulter, James G, Winkelr…	TenPercentOwner	-	Indirect	Sale	16,163	2.75	$44,448.25	4,801,449	4
2022-04-11	Nea, 16 Gp, Llc, Nea Part…	TenPercentOwner	-	Direct	Purchase	2,631,578	1.90	$4,999,998.20	10,421,428	4
2022-04-11	Sonsini, Peter W.	TenPercentOwner	-	Indirect	Purchase	3,580,526	1.90	$6,802,999.40	10,421,428	4
2022-04-11	Makhzoumi, Mohamad	TenPercentOwner	-	Indirect	Purchase	3,580,526	1.90	$6,802,999.40	10,421,428	4
2022-04-11	Behbahani, Ali	TenPercentOwner	-	Indirect	Purchase	3,580,526	1.90	$6,802,999.40	10,421,428	4
2022-04-11	Florence, Anthony A. Jr.	TenPercentOwner	-	Indirect	Purchase	3,580,526	1.90	$6,802,999.40	10,421,428	4
2022-04-11	Sandell, Scott D	TenPercentOwner	-	Indirect	Purchase	3,580,526	1.90	$6,802,999.40	10,421,428	4
2022-04-11	Walker, Paul Edward	TenPercentOwner	-	Indirect	Purchase	3,580,526	1.90	$6,802,999.40	10,421,428	4
2022-04-11	Baskett, Forest	TenPercentOwner	-	Indirect	Purchase	2,631,578	1.90	$4,999,998.20	10,421,428	4
2022-04-11	Chang, Carmen	TenPercentOwner	-	Indirect	Purchase	3,580,526	1.90	$6,802,999.40	10,421,428	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

92.52%

Inst. Shares: 134,700,195

Shares Outstanding: 145,592,901

2025-12-31

96.42%

Inst. Shares: 129,926,207

Shares Outstanding: 134,747,198

2025-09-30

88.97%

Inst. Shares: 129,102,823

Shares Outstanding: 145,104,986

2025-06-30

87.52%

Inst. Shares: 114,079,314

Shares Outstanding: 130,350,391

2025-03-31

71.93%

Inst. Shares: 84,593,398

Shares Outstanding: 117,610,750

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	134,700,195	145,592,901	92.52%
2025-12-31	129,926,207	134,747,198	96.42%
2025-09-30	129,102,823	145,104,986	88.97%
2025-06-30	114,079,314	130,350,391	87.52%
2025-03-31	84,593,398	117,610,750	71.93%
2024-12-31	79,073,156	101,971,873	77.54%
2024-09-30	57,807,172	101,282,228	57.08%
2024-06-30	55,835,110	101,041,573	55.26%
2024-03-31	51,354,857	99,517,212	51.60%
2023-12-31	51,480,681	99,033,373	51.98%
2023-09-30	48,531,113	99,325,540	48.86%
2023-06-30	48,551,035	98,698,579	49.19%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Trevi Therapeutics, Inc. (TRVI) — SEC Financial Statements & Analysis

Trevi Therapeutics, Inc. (TRVI) is a pharmaceutical preparations company, incorporated in DE. Trevi Therapeutics, Inc. trades on Nasdaq as: TRVI. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Trevi Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.03x, a Price-to-Book (P/B) ratio of 9.08x (TTM), at a market cap of $2.92B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.03x
P/B TTM: 9.08x
Market Cap: $2.92B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Trevi Therapeutics, Inc. in?

Trevi Therapeutics, Inc. (TRVI) operates in the Pharmaceutical Preparations industry.

What is TRVI's market cap?

Trevi Therapeutics, Inc. (TRVI) has a market capitalization of $2.92B as of 2026-06-30.

What exchange does TRVI trade on?

Trevi Therapeutics, Inc. (TRVI) trades on the Nasdaq.

Where is Trevi Therapeutics, Inc. incorporated?

Trevi Therapeutics, Inc. is incorporated in DE.